Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

61.85
+1.272.09%
Mar 21 13:21 EST
Volume:925.65K
Turnover:56.74M
Market Cap:11.97B
PE:412.30
High:62.17
Open:60.44
Low:60.26
Close:60.58
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h

Deutsche Bank Adjusts Price Target on Incyte to $60 From $70, Keeps Hold Rating

MT Newswires Live
·
18 Mar

Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires

Insider Monkey
·
18 Mar

Post-Bell | US Stocks Rally; Nvidia Drops 2%; Tesla Sinks 5%; Alibaba Gains 5%; Intel Jumps 7%; Arqit Quantum Soars 57%

Tiger Newspress
·
17 Mar

TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)

TIPRANKS
·
17 Mar

Incyte Corp. Stock Slides 8.6%, Underperforms Competitors

Dow Jones
·
17 Mar

Leerink says Incyte’s povo trial results disappoint, drug likely to be approved

TIPRANKS
·
17 Mar

Why Incyte (INCY) Stock Is Nosediving

StockStory
·
17 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, PepsiCo, Blue Owl Capital

Reuters
·
17 Mar

Incyte Reports Positive Results From Skin Therapy Study; Wells Fargo Cuts Price Target; Shares Drop

MT Newswires Live
·
17 Mar

Incyte Is Today's Worst S&P 500 Stock. Here's Why. -- Barrons.com

Dow Jones
·
17 Mar

Incyte Down Over 9%, on Pace for Largest Percent Decrease Since April 2018 -- Data Talk

Dow Jones
·
17 Mar

Incyte Corp Shares Down 11.5% After Skin Disease Drug Fails to Impress in Late-Stage Studies

THOMSON REUTERS
·
17 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Intel, US Steel, Incyte

Reuters
·
17 Mar

BUZZ-Incyte falls after late-stage data from experimental skin disease drug

Reuters
·
17 Mar

Incyte's Positive Results Not Positive Enough -- Market Talk

Dow Jones
·
17 Mar

Buy Rating for Incyte’s Povorcitinib Despite Mixed Trial Results, Highlighting Potential in Biologic-Experienced Subgroups

TIPRANKS
·
17 Mar

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."